Half Year Results Presentation

In the latest half-year results, Resonance Health reported a 53% revenue increase, reaching $8.0M, with a normalised EBITDA of $1.6M. The company also achieved a profit after tax of $1.5 million, a significant improvement from the previous year. They are making progress in global pharma trials, expanding their clinic network, and have a substantial pipeline of orders and bids. The new innovative technologies like the "Bridge" tool and non-invasive liver fibrosis device show promise for further growth.

Resonance Health's revenue diversification and rapid scaling across three businesses have been positive, leading to a strong CAGR of ~45% since FY23. The company's strategy focuses on expanding their share of the market by broadening therapeutic areas, offering more services to each customer, and acquiring new customers through organic or acquisitive growth.

Investors can look forward to Resonance Health's continued growth in the global clinical trial market, leveraging their deep expertise in liver and metabolic/obesity areas. The company maintains a strong financial position, disciplined cost control, and aims for responsible growth with a target EBITDA margin range of about 25%. If you have any questions about our latest announcement, feel free to ask.